Cargando…

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review

BACKGROUND & OBJECTIVE: Although data on the effects of liraglutide and semaglutide in patients with diabetes have been reviewed, their therapeutic outcomes in obese/overweight individuals without diabetes have not been summarized. We conducted a systematic review to evaluate their effects on th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, You, Park, Andrew, Zhu, Lin, Xie, Wen, Pan, Calvin Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260566/ https://www.ncbi.nlm.nih.gov/pubmed/35813188 http://dx.doi.org/10.1177/20406223221108064

Ejemplares similares

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
por: Alsugair, Hassan A., et al.
Publicado: (2021)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis
por: Kennedy, Cormac, et al.
Publicado: (2023)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
por: Kim, Sun H., et al.
Publicado: (2013)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Barboza, Joshuan J., et al.
Publicado: (2022)

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
por: Gao, Xueqin, et al.
Publicado: (2022)

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis
por: Konwar, Mahanjit, et al.
Publicado: (2022)

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
por: Ghusn, Wissam, et al.
Publicado: (2022)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Cornejo-Estrada, Alejandra, et al.
Publicado: (2023)

Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States
por: Kim, Nina, et al.
Publicado: (2022)

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
por: Garvey, W. Timothy, et al.
Publicado: (2022)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis
por: Smith, Inger, et al.
Publicado: (2022)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes
por: Zhou, Fang, et al.
Publicado: (2023)

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
por: Tan, Hanna Clementine, et al.
Publicado: (2022)

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
por: Heerspink, Hiddo J.L., et al.
Publicado: (2023)

Intestinal Barrier Permeability in Obese Individuals with or without Metabolic Syndrome: A Systematic Review
por: Bona, Mariana Duarte, et al.
Publicado: (2022)

Epidemiology of childhood overweight & obesity in India: A systematic review
por: Ranjani, Harish, et al.
Publicado: (2016)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review
por: Aladel, Alanoud, et al.
Publicado: (2023)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
por: Zhang, Pei, et al.
Publicado: (2019)

Overweight and Obesity in Patients with Congenital Heart Disease: A Systematic Review
por: Willinger, Laura, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Liraglutide restores impaired associative learning in individuals with obesity
por: Hanssen, Ruth, et al.
Publicado: (2023)

The Effect of Including eHealth in Dietary Interventions for Patients with Type 2 Diabetes with Overweight or Obesity: A Systematic Review
por: Geurts, Karlijn A. M., et al.
Publicado: (2023)

Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
por: Lu, Yuan, et al.
Publicado: (2022)

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
por: Kosiborod, Mikhail N., et al.
Publicado: (2022)

Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus
por: Kohut, Taisa, et al.
Publicado: (2021)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s275cq9lv2cu35rok9c60j41hh